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VIEWS AND REVIEWS
Surgical and postmortem pathology studies: 
contribution for the investigation of  
temporal lobe epilepsy
Patologia cirúrgica e post mortem: contribuição para a investigação da epilepsia do  
lobo temporal
Luís Otávio Sales Ferreira Caboclo1, Rafael Scarpa Neves1, Anaclara Prada Jardim1,  
Ana Paula Andrade Hamad1, Ricardo Silva Centeno1, Carmen Lucia Penteado Lancellotti2,  
Carla Alessandra Scorza3, Esper Abrão Cavalheiro3, Elza Márcia Targas Yacubian1, Américo Ceiki Sakamoto4
Diagnostic evaluation of epilepsy patients includes clin-
ical history, neurological examination, seizure semiology 
analysis, neuropsychological assessment, as well as auxil-
iary diagnostic tools, such as electroencephalogram (EEG), 
structural neuroimaging (computed tomography and mag-
netic resonance imaging), and functional neuroimaging 
( functional magnetic resonance, single-photon emission 
computed tomography, positron emission tomography, and 
magnetic resonance spectroscopy).
Investigation of patients with both focal and generalized 
epileptic syndromes may also include, whether for clini-
cal or research purposes, pathological studies of the brain 
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ABSTRACT
Pathology studies in epilepsy patients bring useful information for comprehending the physiopathology of various forms of epilepsy, as well 
as aspects related to response to treatment and long-term prognosis. These studies are usually restricted to surgical specimens obtained 
from patients with refractory focal epilepsies. Therefore, most of them pertain to temporal lobe epilepsy (TLE) with mesial temporal sclerosis 
(MTS) and malformations of cortical development (MCD), thus providing information of a selected group of patients and restricted regions 
of the brain. Postmortem whole brain studies are rarely performed in epilepsy patients, however they may provide extensive information on 
brain pathology, allowing the analysis of areas beyond the putative epileptogenic zone. In this article, we reviewed pathology studies per-
formed in epilepsy patients with emphasis on neuropathological findings in TLE with MTS and MCD. Furthermore, we reviewed data from 
postmortem studies and discussed the importance of performing these studies in epilepsy populations.
Key words: epilepsy, temporal lobe, mesial temporal sclerosis, pathology, surgical.
RESUMO
Estudos de patologia em pacientes com epilepsia trazem informações úteis para compreender a fisiopatologia de várias formas de epilep-
sia, bem como aspectos relacionados ao tratamento e ao prognóstico a longo prazo. Esses estudos são usualmente restritos a espécimes 
cirúrgicos obtidos de pacientes com epilepsias focais refratárias. Portanto, a maioria diz respeito à epilepsia do lobo temporal (ELT) com 
esclerose mesial temporal (EMT) e às malformações do desenvolvimento cortical (MDC). Desse modo, fornecem informações sobre um grupo 
selecionado de pacientes e sobre regiões restritas do cérebro. Raramente são realizados estudos post mortem do cérebro inteiro em pacien-
tes com epilepsia; entretanto, eles podem prover informações relevantes sobre patologia cerebral, permitindo a análise de áreas além da 
zona epileptogênica putativa. Neste artigo, foram revisados estudos de patologia feitos em pacientes com epilepsia, com ênfase nos achados 
neuropatológicos em ELT com EMT e MDC. Foram revisados, ainda, dados de estudos post mortem e discutiu-se a importância da realização 
desses estudos em populações de pessoas com epilepsia.
Palavras-Chave: epilepsia do lobo temporal, esclerose mesial temporal, patologia cirúrgica.
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tissue. These studies may bring useful information for com-
prehending the physiopathology of various epilepsy forms, 
as well as aspects related to response to treatment and 
long-term prognosis.
PATHOLOGY STUDIES IN EPILEPSY PATIENTS
Pathology studies in epilepsy patients are usually restrict-
ed to surgical specimens obtained from patients with refrac-
tory focal epilepsies. Therefore, the vast majority address 
temporal lobe epilepsy (TLE), due to hippocampal sclero-
sis (HS), and focal epilepsies, due to malformations of cor-
tical development (MCD), given that these pathologies con-
stitute the most common etiologies of surgically amenable 
epilepsies1. These studies thus provide information of a se-
lected group of patients and restricted regions of the brain. 
Nevertheless, they can bring important data concerning the 
physiopathology of focal epilepsies and also about factors re-
lated to postsurgical prognosis in these patients.
Whole brain studies in postmortem examination are 
rarely performed in epilepsy patients, but they may provide 
extensive information on brain pathology2,3, allowing the 
analysis of areas beyond the putative epileptogenic zone4,5. 
However, this sort of study is rare even in centers specialized 
in the care of epilepsy patients6. 
TEMPORAL LOBE EPILEPSY AND MESIAL 
TEMPORAL SCLEROSIS
TLE is the most frequent focal epileptic syndrome in 
adults7. TLE patients are classified, according to clinical and 
electrographic features, in two separate groups: mesial TLE 
and lateral or neocortical TLE8. Mesial TLE expresses itself 
through epileptic seizures originated in mesial structures of 
the temporal lobe, usually the hippocampal formation and 
occasionally the amygdala6. HS is the most frequent underly-
ing pathological substrate in TLE9. Mesial TLE with HS con-
stitutes a distinct epileptic syndrome, with well-defined clini-
cal, neuroimaging, and prognostic features6.
Pathological studies of the temporal lobe tissue resected 
during surgeries for treatment of drug-resistant mesial TLE 
revealed a pattern of sclerosis or neuronal loss in the hip-
pocampal formation9. The hippocampus in these patients 
presents neuronal loss in subfields CA 1 and 4, with relative 
sparing of CA 2 and granular cells of the dentate gyrus (DG). 
Reactive astrogliosis is also observed, which associated with 
neuronal loss leads to the aspect of atrophy and tissue hard-
ening. This pathological aspect was described in 188010 and 
later named Ammon’s Horn Sclerosis2. The more marked 
neuronal loss in subfields CA 1 and 4 was confirmed by quan-
titative pathological studies11,12. Besides the hippocampal 
formation, other mesial structures may present neuronal loss 
and gliosis, including the entorhinal cortex13 and the amyg-
dala14,15. The expression mesial temporal sclerosis (MTS) was 
introduced as an alternative to HS, denoting atrophy of other 
structures beyond the hippocampal formation16. However, its 
association with injury of other mesial structures should be 
confirmed by pathological examination, whether in surgical 
or autopsy specimens, so that MTS is used properly9. 
TLE and MTS association is well-established, although 
it is still discussed if MTS constitutes the indispensable sub-
strate for seizure generation of it. On the other hand, it is 
the consequence of repeated epileptic seizures9. The role of 
an initial precipitant insult (IPI) such as febrile seizures or 
traumatic brain injury is also yet to be defined. It is possi-
ble that, in MTS, the neuronal loss encountered in surgical 
specimens may represent a combination of an acute loss by 
the time of the IPI and additional losses resulting from re-
peated seizures17. 
MTS is not inexorably associated with TLE. There is a 
group of patients in whom MTS is indeed associated with 
the typical features of mesial TLE. In these patients, neuro-
nal loss and synaptic reorganization probably constitute the 
physiopathological abnormality that originates clinical sei-
zures. This situation is sometimes referred to as “primary 
HS”. However, a distinct group of patients may be identified, 
in whom pathological features compatible with MTS are ob-
served, though without the typical clinical characteristics of 
TLE. In this latter group, MTS may be secondary to seizures 
originated from extratemporal cortical areas5,18.
In addition, MTS is not necessary for the occurrence of 
temporal lobe seizures. Other etiologies may be identified, 
such as MCD or tumors. Yet, in some patients, a clinical syn-
drome undistinguishable from TLE with MTS is observed, 
though with no signs of MTS in neuroimaging studies and 
pathological examination. This condition has been named 
“paradoxical TLE”18.
There is enough data from animal models19 and human 
studies20,21 to affirm that prolonged seizures and status epi-
lepticus may injury the hippocampus and eventually lead to 
MTS. However, in humans, MTS is not the inevitable conse-
quence of repeated seizures and the exact time course of the 
relation between MTS and the occurrence of seizures is not 
precisely defined5.
TEMPORAL LOBE EPILEPSY: SURGICAL 
PATHOLOGY
In TLE patients with drug-resistant seizures, surgery 
is better than clinical treatment with respect to seizure 
control and quality of life22. TLE with MTS constitutes the 
most frequent indication of surgical treatment in adults7. 
Approximately two third of patients become seizure free 
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after surgery7,23-25. However, the remaining third continues to 
have disabling seizures, and this number seems to increase 
with longer follow-up periods26-28. 
Several features have been studied as prognostic factors, 
but conflicting conclusions have been reached, probably due 
to methodological issues and population heterogeneity in 
different studies25,27,28. Bilateral hippocampal abnormalities 
and extratemporal injuries have been implicated in poor sur-
gical prognosis in operated TLE patients25,29. Therefore, pa-
thology studies in TLE with MTS may bring important con-
tributions for the elucidation of the mechanisms involved in 
the response to surgical treatment. 
The pattern of neuronal loss in the resected hippocam-
pal formation may correlate with prognosis. Atypical pat-
terns of MTS have been recognized for decades, initially on 
postmortem pathology series2 and later in surgically resect-
ed hippocampal specimens30. These atypical patterns may be 
associated with worse surgical outcome12,31. Their identifica-
tion before surgery, through advanced neuroimaging tech-
niques32, might help defining surgical programming. 
Blumcke et al.12 proposed a new system of histological 
classification in TLE patients submitted to surgical treat-
ment. They studied surgical specimens from 178 patients, 
who were divided into five groups, according to the pattern 
of neuronal loss in the hippocampus and DG:
• no MTS;
• MTS type 1a: classic hippocampal sclerosis, character-
ized by neuronal loss in subfields CA 1 and 4, with more 
marked loss in CA 1;
• MTS type 1b: severe hippocampal sclerosis, with marked 
diffuse neuronal loss;
• MTS type 2: CA 1 sclerosis, with neuronal loss practically 
restricted to CA 1;
• MTS type 3: end folium sclerosis, with neuronal loss re-
stricted to the DG hilus.
After a minimum six-month follow-up, MTS patterns cor-
related to prognosis with respect to seizures: patients with 
MTS types 1a and b had the best prognosis (86 and 85% of pa-
tients free of seizures, respectively), followed by patients with 
no MTS (71%). It is worth remarking that 12 out of the 34 pa-
tients with no MTS had other lesions in close proximity with 
the hippocampus, including slow growth tumors and focal 
cortical dysplasia. Patients with MTS types 2 and 3 had the 
worst prognosis (50 and 43% free of seizures, respectively). 
The correlation between MTS and prognosis persisted after 
one year of follow-up. 
Thom et al.33 reviewed and classified the patterns of MTS 
in 165 operated TLE patients. Atypical patterns of MTS, in-
cluding end folium sclerosis and CA 1 predominant (CA1p) 
sclerosis, were found in 28% of patients, whereas 18 patients 
had no pathological signs of MTS. Postsurgical prognosis was 
worse in patients with CA 1 predominant neuronal loss, as 
in those without signs of MTS. Jardim et al.34 studied 66 TLE 
with MTS patients, analyzing clinical characteristics and 
MTS patterns. Occurrence of initial precipitating insult, as 
well as better postoperative seizure control, was associated 
with classical (type 1a) and severe (type 1b) patterns of MTS. 
These studies confirmed that the recognition and definition 
of different patterns of neuronal loss (Fig 1) in the hippocam-
pus of TLE patients submitted to surgical treatment may be 
useful in the definition of postsurgical prognosis.
Hence, other neuropathological findings found in surgi-
cal specimens may bring information regarding epileptogen-
esis in TLE or provide data relevant to surgical prognosis. 
Granule cell dispersion (GCD) and temporal lobe sclerosis 
(TLS) are among these findings.
GCD is a common phenomenon, occurring in up to 40% 
of the hippocampi of TLE patients6,12,35. It is characterized by 
broadening of the granule cell layer of the DG12,36. Criteria for 
determining dispersion vary from qualitative impressions of 
the layer width to more objective quantitative measures37. In 
addition to GCD, the DG may present a bilaminar pattern, 
defined as two parallel layers of granule cells, the inner band 
considered as remnant of the original DG and an additional 
ectopic outer band towards the molecular layer37 (Fig 2).
Houser first described GCD in TLE patients’ hippocampi, 
in which the border between granule cell and molecular layers 
was not distinct, with numerous granule cell somata extend-
ing into the molecular layer. GCD may depend on the neuro-
nal loss in the DG hilus38, although it may also be observed in 
patients with widespread cortical malformation, even in the 
Fig 1. Hippocampal formation in control and temporal lobe 
epilepsy patients and patterns of hippocampal sclerosis (all 
NeuN-stained sections). (A) Control specimen. (B) No mesial 
temporal sclerosis: no loss of neurons detected in all subfields 
(hippocampus subfields 1 to 4). (C) Mesial temporal sclerosis 
type 1a (classic hippocampal sclerosis): significant neuronal 
loss in hippocampus subfields 1 and 4 with relative sparing 
of neurons in hippocampus subfield 2. (D) Mesial temporal 
sclerosis type 1b (severe hippocampal sclerosis): neuronal 
loss in all subfields and in the dentate gyrus. (E) Mesial 
temporal sclerosis type 2 (hippocampus subfield 1-sclerosis): 
neuronal loss predominating in hippocampus subfield 1. Scale 
bars: 1 mm.
A
C D F
B
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absence of hippocampal cell loss, suggesting a maldevelop-
ment disorder39. Early seizure onset or status epilepticus at an 
initial stage of the disease have been associated with GCD40,41. 
GCD may be a consequence of enhanced proliferation of gran-
ule cell precursors as a result of seizures42,43. Its clinical rele-
vance is uncertain, as is its relation to surgical prognosis12,33,37. 
Dysmorphic neurons and interneurons may be en-
countered in the DG of TLE with MTS patients, along with 
GCD44-46. Also, CD34-positive balloon cells have been de-
scribed as being associated with GCD47, which raises the 
hypothesis of focal cortical dysplasia (FCD) localized in the 
DG in these patients. On the other hand, CD34 expression 
may just be a transitory phenomenon in the GCD process, 
possibly related to increase in neurogenesis and prolifera-
tion of progenitor cells of the glia43.
Neuronal loss and gliosis, which were observed in the 
hippocampal formation of TLE patients submitted to surgi-
cal treatment, may extend beyond this formation and involve 
the uncus, amygdala, parahippocampal gyrus, and temporal 
neocortex48. However, the frequency, severity, and distribu-
tion of neuronal loss and gliosis in the temporal neocortex – 
characterizing TLS — are yet to be precisely defined. 
Thom et al.49 studied 272 TLE with MTS patients submit-
ted to surgical treatment for refractory seizures. In 30 patients 
(11%), histological pattern compatible with TLS was identi-
fied: neuronal loss in layers II and III of the temporal cortex, 
with correspondent laminar gliosis in those affected by neu-
ronal loss. Neuronal loss and gliosis were typically associated 
with structural abnormalities in layer II, such as abnormal 
neuronal orientation and aggregation. In 40% of the cases, a 
TLS gradient was observed with more marked involvement 
toward the temporal pole, which would suggest involvement 
of hippocampal projection pathways. Febrile seizures were 
more frequent in patients with TLE when compared to those 
without this pathological abnormality (73 and 36%, respec-
tively). There was no difference between the two groups re-
garding postsurgical prognosis. The authors concluded that 
in these series of TLE with MTS patients, TLS was consid-
ered as part of the MTS spectrum, not as a second lesion as-
sociated with HS or dual pathology. Structural abnormalities 
observed in layer II probably represent organizational altera-
tions related to the process of TLS, however they do not con-
stitute a MCD in its strict sense.
Neuroimaging studies revealed that abnormalities in the 
temporal lobe may coexist with MTS50,51. The temporal pole 
in TLE with MTS patients may present signal abnormalities 
in up to 75% of the cases52. Signal abnormalities and atrophy 
of the temporal pole are ipsilateral to MTS in the majority of 
patients53. Despite the alterations observed in neuroimaging 
studies, neuropathological studies in patients with such alter-
ations have been inconclusive51. Depth EEG studies revealed 
that the temporal pole cortex may play a pivotal role in origi-
nating seizures in TLE patients, with ictal discharges preced-
ing or occurring simultaneously with discharges originated 
from the ipsilateral hippocampus50. In addition to temporal 
lobe cortex alterations, other abnormalities may be observed 
in the extratemporal cortex in patients with TLE-MTS54. 
The association between temporal lobe development ab-
normalities — including focal cortical dysplasia (FCD) — and 
MTS is also recognized55-57. Therefore, although MTS is more 
commonly seen as an acquired pathology, presence of hippo-
campal malformation as a substrate for further development 
of MTS and TLE is frequently questioned55,56,58.
POSTMORTEM PATHOLOGY STUDIES
Postmortem pathology studies, although rare in epilep-
sy patients6, may provide very useful information, especially 
when pathological findings are correlated to clinical and neu-
roimaging data.
Pathological studies in TLE with MTS are usually limited 
to the examination of one of the hippocampi obtained dur-
ing surgery for treatment of drug-resistant epilepsy. This ap-
proach bears two important limitations: firstly, it does not 
allow the study of other areas of the brain, particularly the 
contralateral hippocampus; and secondly, only highly-select-
ed patients, fulfilling strict criteria for indication of surgical 
treatment, are included in these studies59. On the other hand, 
postmortem studies provide global access to brain tissue, in-
cluding the hippocampus which is contralateral to that pri-
marily defined as being epileptogenic in TLE patients5,6. 
Margerison and Corsellis2, in a seminal paper published 
in 1966, studied the brains of 55 epilepsy patients, with 
Fig 2. Histopathological findings in dentate gyrus of controls 
and temporal lobe epilepsy patients (NeuN-stained sections). 
(A) Control. (B) No granule cell dispersion: granule cells are 
densely packed and have a distinct border with the molecular 
layer. (C) Granule cell dispersion: the cells are dispersed and 
spread into the molecular layer. (D) Bilamination: granule cells 
are dispersed, but with a cell free zone between both layers. 
Scale bars: 100 µm.
A
C D
B
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emphasis on the temporal lobes. Twenty-six patients had 
TLE. Both hippocampi were examined in all cases, and MTS 
was identified in 36 of the 55 patients. Fourteen out of the 
36 had a pattern compatible with end folium gliosis (EFG), 
while 22 showed the classical features of HS. Among the lat-
ter 22 patients, 4 had bilateral and 18 unilateral HS, includ-
ing eight with contralateral EFG. Overall, almost half of the 
patients (17/36) had bilateral hippocampal abnormalities, 
whether classical HS or EFG.
Postmortem series may also bring information on the 
possible relation between repeated seizures and neuronal 
loss in the hippocampus. Dam60 studied the brains of 20 ep-
ilepsy patients and quantified the hippocampal neurons. 
Epilepsy patients had fewer neurons in their hippocampi, 
when compared to controls. Neuronal loss predominated in 
the end folium and was influenced by the occurrence of gen-
eralized seizures and duration of epilepsy. Nixon et al.61 re-
ported the case of a 35-year-old man who died as a conse-
quence of status epilepticus. Postmortem neuropathological 
examination disclosed marked neuronal loss in both hippo-
campi, which was considered a direct result of the status epi-
lepticus, since the patient had no previous history of epilepsy, 
the first magnetic resonance imaging was normal, and there 
was no evidence of hypoxic lesions or infectious encephalitis. 
Pohlmann-Eden et al.20 reported the case of a man who suf-
fered a prolonged status epilepticus, in a five-month period. 
Sequential magnetic resonance imaging exams showed signs 
of progressive lesion in both hippocampi, which was con-
firmed by autopsy, revealing bilateral HS and thus providing 
support for the hypothesis that prolonged status epilepticus 
might cause hippocampal lesion in humans.
There is however evidence on the contrary. Thom et al.5 
conducted a stereological analysis of the hippocampi of 28 
patients with poorly controlled seizures, and identified a 
group of patients without any significant neuronal loss, de-
spite decades of frequent generalized seizures, including epi-
sodes of status epilepticus. The authors concluded that sei-
zures do not inevitably cause hippocampal lesion. In a series 
of 15 patients with idiopathic generalized epilepsy, postmor-
tem neuropathological examination failed to disclose signs of 
HS, despite the long duration of epilepsy; a quantitative anal-
ysis performed in ten of these patients did not show signifi-
cant differences when compared to age-matched controls62,63.
There are a few hypotheses that try to explain why sur-
gery fails to render TLE with MTS patients seizure free in ap-
proximately one third of cases: residual hippocampus with 
HS in the side of surgery; contralateral hippocampal abnor-
malities; or presence of epileptogenic lesion beyond the re-
sected temporal lobe64,65. Whole brain studies may help eval-
uating these hypotheses. 
Babb66 reported two cases of bilateral and asymmetric 
HS in patients submitted to autopsy. In both patients, there 
was bilateral hippocampal neuronal loss, although in one the 
neuronal loss was only confirmed in both hippocampi after 
cell counting, because in one side neuronal loss was mild. 
Mathern et al.67 reported one patient who died few weeks 
after being submitted to surgical treatment for drug-resis-
tant TLE. The hippocampus resected during surgery showed 
a pathological pattern consistent with HS, while the con-
tralateral hippocampus, studied in the autopsy, showed an 
atypical pattern of HS with less marked neuronal loss when 
compared to the operated side. Furthermore, mossy fiber 
sprouting (MFS) was observed only in the surgically resected 
side. The authors concluded that in cases of asymmetric neu-
ronal loss, the MFS presence was indicative of epileptogenic 
hippocampus.
MFS is one of the cellular abnormalities in the hippo-
campal formation that may indicate seizure generation in 
the mesial temporal structures in TLE-patients68-70. GCD 
in the DG38 and changes in the neuropeptide Y (NPY) net-
work31 are also among these abnormalities, which can be 
found uni or bilaterally in the hippocampi of TLE patients.
Thom et al.4 studied 25 epilepsy patients, who were sub-
mitted to postmortem pathological examination. Nine of 
them were seizure-free before death for periods up to 34 years. 
The authors aimed at studying synaptic reorganization in the 
DG, in order to determine if the process was bilateral; at in-
vestigating its association with several degrees of MTS and 
with different epileptic syndromes; and at analyzing if this re-
organization persisted after long periods of seizure remission. 
Cellular reorganization in the DG was assessed in both hip-
pocampi of all patients through immunohistochemistry with 
dynorphin (to demonstrate MFS) and NPY. Abnormal NPY 
patterns and bilateral MFS were observed in 15 patients, in-
cluding those with unilateral and bilateral HS, whether sym-
metrical or asymmetrical. These findings were encountered 
in patients with mesial TLE and other epileptic syndromes, 
and also in those with long periods of seizure freedom pre-
ceding death. Still, MFS was observed in patients without HS. 
The authors concluded that synaptic reorganization in the 
DG may be a bilateral and persistent process in epilepsy pa-
tients; MFS may occur independently of the neuronal loss ob-
served in HS; and MFS and abnormal patterns of NPY prob-
ably happen as a response to epileptic seizures and do not 
represent a critical factor in the generation of these seizures.
In addition to bilateral hippocampal abnormalities, tem-
poral lesions extending beyond the hippocampus, as well as 
extratemporal ones, may also explain seizure recurrence af-
ter surgery in TLE with MTS patients64. In the conclusion sec-
tion of their 1966 paper, Margerison and Corsellis remarked 
the “...need to see beyond the temporal lobes and to take 
into account the possible importance of damage in other 
parts of the brain as well”2. The injuries diagnosis associat-
ed with MTS has great clinical importance, due to its impact 
in response to clinical treatment71 and programming of sur-
gery72,73. The association of MTS plus another lesion out of the 
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hippocampus constitutes dual pathology73,74, which was seen 
in 5 to 30% of patients with focal epilepsy and drug-resistant 
seizures74. MTS may be associated with several other pathol-
ogies, such as MCD, slow growth tumors, vascular malforma-
tions, porencephaly, and gliosis72-76. 
Macroscopic and microscopic abnormalities compat-
ible with the diagnosis of MCD may coexist with MTS in TLE 
patients and constitute the most frequent type of dual pa-
thology74. In the recently proposed classification of FCD77, its 
association with MTS is classified as type IIIa. Dysplastic ab-
normalities, such as cortical laminar disorganization, pres-
ence of dysmorphic neurons, and balloon cells in the tempo-
ral neocortex of TLE-MTS patients have been described78,79, 
although their clinical relevance and role in the epileptogen-
esis in these patients remain undefined80. Simultaneous re-
cording of the hippocampus and dysplastic abnormalities in 
the temporal neocortex with depth electrodes and subdural 
strips showed that even subtle dysplastic lesions are epilep-
togenic72. However, is it still disputed in the literature if the 
coexistence of MTS and dysplastic lesions predispose to a 
poor surgical prognosis81, or if the resection of both lesions 
may lead to adequate seizure control after surgery80. In such 
cases, surgical decision – resection of the hippocampus, the 
FCD or both – must be based on clinical, neurophysiological, 
and neuroimaging data74.
Whether associated with MTS or isolated, MCD consti-
tutes an important etiology of drug-resistant seizures71,82,83. 
Magnetic resonance imaging is the best available method 
for diagnosis84, although one quarter of all patients submit-
ted to surgical treatment in whom pathological examination 
confirmed the diagnosis of MCD had normal preoperative 
magnetic resonance imaging exams82,84. MCD may thus go 
undetected by magnetic resonance imaging; patients with 
severe epilepsies of supposedly unknown causes may in fact 
have MCD. Whole brain pathological studies might diagnose 
MCD, which were previously missed in vivo.
As well as MCD, other pathological abnormalities may 
be missed by usual diagnostic methods in epilepsy patients. 
Therefore, whole brain examination during autopsy may 
yield new information in these cases.
Blanc et al.85 conducted a postmortem examination in six 
patients with TLE-MTS, along with three epilepsy patients 
without MTS, and four nonepilepsy controls. MTS was uni-
lateral in four of them and bilateral in two. Cases with signifi-
cant second or acquired pathology, such as contusional brain 
injury, cerebrovascular or neurodegenerative diseases, were 
excluded from the study. In all cases and controls, cortical 
and white matter regions from both hemispheres were sam-
pled, selected according to known hippocampal afferent or 
efferent projection sites. A quantitative analysis of the corti-
cal tissues was conducted in order to detect acquired neo-
cortical pathology, including gliosis and microgliosis, by use 
of specific immunomarkers. Higher staining fractions were 
observed for all markers in the cortex and white matter, both 
in TLE-MTS and non-MTS epilepsy patients when compared 
to controls. Gliosis and microgliosis were more marked in 
temporal and frontal poles and orbitrofrontal cortex in epi-
lepsy patients, without clear relation to hippocampal path-
ways. This paper demonstrated the presence of previously 
undetected cortical pathology in epilepsy patients, which 
might be related to factors such as cortical injury associated 
with seizures. These cortical abnormalities may contribute 
to seizure generation in these patients and, in operated TLE-
MTS patients, they might be factors leading to poor postop-
erative outcome.
There is not yet a group of patients in whom etiological 
diagnosis is not determined during life, despite clinical inves-
tigation and neurophysiological, neuroimaging, and labora-
torial data. These patients are grouped under the expression 
cryptogenic epilepsy86. Particularly in such patients, neuro-
pathological examination is often seen as the latest available 
resource for diagnostic conclusion. However, there are still 
some patients with long-standing severe epilepsies and nor-
mal whole brain neuropathological examination. In these pa-
tients, it is possible that the pathological abnormalities that 
cause seizures are beyond the sensitivity of the habitual neu-
ropathological examination. They may happen in cellular, 
synaptic, or molecular levels. Perhaps a “new pathology” will 
be needed to help further identify the cause of seizures in pa-
tients with cryptogenic epilepsies.
In conclusion, postmortem whole brain neuropathologi-
cal examination may help answer important questions, such 
as: what are the most common pathological findings in pa-
tients with refractory epilepsy?; what is the importance of le-
sions associated with the putative epileptogenic lesion?; what 
happens to the brain in chronic epilepsies, with seizures re-
sistant to clinical and surgical treatments?; can seizures and 
seizure-related traumatic brain injuries bring additional mor-
bidity to these patients?; and is there a progression of the le-
sion if the patient is seizure-free for a long time before death? 
Studies correlating detailed clinical data of epilepsy pa-
tients with neuropathological findings will certainly offer an 
opportunity of answering, if not all, at least many of these 
questions.
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